Biologics And Biosimilars Market : Facts, Figures and Analytical Insights 2021-2026

The Biologics And Biosimilars Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Global Biologics and Biosimilars market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 178420 million in 2020. Over the next five years the Biologics and Biosimilars market will register a 5.3% CAGR in terms of revenue, the global market size will reach US$ 219110 million by 2026.

Get Sample Copy Of This Report + All Related Graphs (Covid-19 Update):

https://www.marketinsightsreports.com/reports/05202914759/global-biologics-and-biosimilars-market-growth-2021-2026/inquiry?source=OpenPr&Mode=12            

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Biologics And Biosimilars Market: Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, 3sbio, Changchun High Tech, CP Guojian, Biotech, Gelgen, Innovent, Dong Bao, Ganlee, United Laboratories and others.

Some Of The Recent Developments In The Market Are As Follows:

Roche hit for $6.3bn due to biosimilar competition

Monday, February 8, 2021: Roche announced in full year results for 2020 that biosimilars to Herceptin (trastuzumab), Avastin (bevacizumab), and MabThera/Rituxan (rituximab) dented sales by CHF 5.7 billion ($6.34 billion) worldwide. Roche group’s CEO, Severin Schwan, commented in an investor call after the results were revealed that “the impact of biosimilars was significant, somewhat higher than we originally expected.”

As a result, sales in the company’s pharmaceuticals division decreased by 8% to CHF 44.5 billion compared to the previous year. A reduced impact is expected to be felt in 2021, though a CHF 4.6 billion fall in sales is still expected from the same three products.

Bill Anderson, CEO of Roche Pharmaceuticals, concluded, “I think we’ve seen the worst that it can get.” He added that the company had previously estimated a sales impact of CHF 4 billion in the US, Japan, and Europe – with the actual figure for 2020 being CHF 5.1 billion.

AbbVie’s successful hard-ball with Humira legal strategy unlikely to spawn similar efforts; potential appeals outcome unclear

19 Feb 2021 -- AbbVie’s successful efforts to impede Humira’s (adalimumab) biosimilar entry are difficult for other pharma players to emulate given its relatively large patent portfolio and aggressive legal strategy, said legal experts.

An antitrust complaint brought against AbbVie was dismissed in June 2020 in a Chicago district court and is currently under appeal in the US Court of Appeals for the Seventh Circuit. While the appeal is ongoing, experts debated a potentially different outcome given the strong original judgement.

AbbVie’s aggressive stance in pursuing a broad patent portfolio would be difficult to repeat, especially for smaller biosimilar companies with limited resources. Moreover, Humira’s relatively early entry and applicability in numerous indications has allowed for the accumulation of an extensive patent portfolio, which differentiates it from other high-profile biologics in the respective therapeutic spaces, experts said.

Humira occupies an outsized position in the biologic and biosimilar landscape, as it netted $16.11bn in 2020, an increase of 8.4% over the previous year. The drug was first approved in December 2002 to treat rheumatoid arthritis and its uses span across 16 indications for adult and paediatric patients.

Amgen's rise in biosimilar space may signal turning tide for US market

25 Sep, 2019: Amgen Inc. is fostering its biosimilar pipeline to become a powerhouse in the fledgling U.S. copycat arena, building upon global sales that have doubled since the end of 2018.

Biosimilars are medications comparable to a branded biologic counterpart. In the U.S., the biosimilar market has lagged behind that of Europe, where a framework was defined in 2005. The U.S. only established a pathway in 2010.

Taking advantage of these early stages of the U.S. biosimilar market is a good investment for Amgen and the healthcare system as a whole, Chad Pettit, executive director of global value and access for the company's biosimilar programs, told S&P Global Market Intelligence.

Global Biologics And Biosimilars Market Split by Product Type and Applications:

This report segments the market on the basis of Types are:

Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others

On the basis of Application, the market is segmented into:

Tumor
Diabetes
Cardiovascular
Hemophilia
Others

Buy The Report:
https://www.marketinsightsreports.com/report/purchase/05202914759?mode=su?source=OpenPr&Mode=12                  

Regional Analysis For Biologics And Biosimilars Market:

For comprehensive understanding of market dynamics, the global Biologics And Biosimilars market is analyzed across key geographies namely:

North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Biologics And Biosimilars Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2021–2027.                 

Key Points of Biologics And Biosimilars Market Table of Contents:

-Market Overview: The report begins with this section where a product overview and key content on the product and application segments of the global Halal Foods market are provided. The highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

-Competition by company: Here we analyze the competition of the global Biologics And Biosimilars market, by company price, revenue, sales and market share, market share, competitive landscape, and latest trends, mergers, expansions, acquisitions, and market share of top companies.

-Company Profile and Sales Data: As the name suggests, this section provides sales data and useful information about the business of key players in the global Biologics And Biosimilars market. It describes the key businesses of gross margin, price, revenue, products and specifications, types, applications, competitors, manufacturing base, and key players operating in the global Biologics And Biosimilars market.

-Market Forecast: Here the report provides a full forecast for the global Biologics And Biosimilars market by product, application, and region. It also provides global sales and revenue forecasts for all years in the forecast period.

-Research Results and Conclusion: One of the last sections of the report where analyst findings and findings are provided.

For More Information On This Report, Please Visit: https://www.marketinsightsreports.com/reports/05202914759/global-biologics-and-biosimilars-market-growth-2021-2026?source=OpenPr&Mode=12         

Due to the onset of COVID-19 pandemic, several economies across the world have experienced harsh economic downturn. The industrialists across North America, Europe, Asia Pacific, Latin America and Middle East and Africa were facing problems due to changing preferences of the customers and demand fluctuation. The market research report covers pre-Covid-19 data for the «Keyword» market in years 2018 and 2020. Further, the report also covers forecast Covid-19 data from 2021 to 2027, which provides future outlook of the market for the manufacturers and suppliers.

Browse Related Reports:

Biosimilars Insulin Market:

https://www.marketinsightsreports.com/reports/05282941318/global-biosimilars-insulin-sales-market-report-2021?source=OpenPr&Mode=12               

HGH Biosimilars Market:

https://www.marketinsightsreports.com/reports/05222923119/global-hgh-biosimilars-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026?source=OpenPr&Mode=12                   

G-CSF Biosimilars Market:

https://www.marketinsightsreports.com/reports/05222923098/global-g-csf-biosimilars-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026?source=OpenPr&Mode=12           

Customization Of The Report:

MarketInsightsReports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.     

If you have any questions about any of our “Biologics And Biosimilars market report” or would like to schedule a personalized free demo of Biologics And Biosimilars market report, please do not hesitate to contact me at irfan@marketinsightsreports.com.

Best wishes,

Irfan Tamboli

Head of Sales Operations

Market Insights Reports

Tel: + 1704 266 3234 | +91-750-707-8687

Email: sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides Global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.